President Trump’s threat to impose steep tariffs — up to 150 percent within 18 months, possibly rising to 250 percent — on imported pharmaceutical products has set off alarms throughout the healthcare and life sciences sectors.
While framed as a strategy to promote domestic manufacturing and reduce US drug prices, experts warn that such a move could have the opposite effect: raising costs, disrupting supply chains, and stalling innovation in drug development.
Costs and disruption
The US imports more than $200 billion in pharmaceuticals annually. A 25 percent tariff alone could add up to $46 billion in additional drug costs per year, according to a recent JAMA study. Distributors and generics makers — who often operate on margins under 1 percent — say they won’t be able to absorb the cost.
The Healthcare Distribution Alliance (HDA) warned that the tariffs would “likely worsen shortages of important medications,” particularly for generics, and “costs will be passed down to payers and patients."
Because generic drugmakers already function with razor-thin profit margins, sudden spikes in operating costs leave little room for investment in manufacturing efficiency, quality upgrades, or process innovations that could improve reliability and reduce waste.
Without these advancements, the sector’s ability to maintain a steady, diverse supply is diminished risking both higher prices and prolonged shortages, and ultimately limiting the competitive pressure that keeps medicines affordable.
Innovation in peril
Beyond the immediate risks to accessibility, the broader drug development pipeline is already under strain. Drug development is notoriously expensive and slowing — a trend known as Eroom’s Law, where the cost of bringing a new therapy to market doubles roughly every nine years.
In this climate, tariffs present fresh hurdles. Reuters reported that the CEO of Eli Lilly warned that absorbing tariff costs would likely force companies to cut research funding, undermining long-term innovation. In the same vein, the CEO of Sanofi admitted higher R&D costs and the potential necessity of direct-to‑patient sales to relieve pricing pressure.
Drug discovery and development play a critical role in safeguarding global health, especially as pressing threats like antibiotic resistance continue to escalate. Without new, effective treatments, common infections could once again become deadly, threatening decades of medical progress.
But innovation in pharmaceutical research is essential not only to address emerging drug-resistant pathogens, but also to deliver faster, more precise therapies for a wide range of diseases.
High barriers, slow payoff
While the administration argues that tariffs will reshore drug production, only 12 percent of US active pharmaceutical ingredients are domestically manufactured, and building out capacity would require billions in public and private investment.
Berkeley Research Group (BRG) supply-chain consultant Ed Buthusiem pointed out in an article that “If tariffs make overseas production economically disadvantageous, companies might bring more production back to the US. But tax burden is just one of several factors that go into site selection — labor, geopolitics, climate, and environmental factors are also considerations.”
High stakes, limited upside
Pharmaceutical consultants and public health experts agree: blanket tariffs pose significant risk without delivering strategic clarity.
While the idea of “bringing manufacturing home” has been touted as promising in theory, poor execution could create more problems than it solves.
